CAS No. |
508-75-8 |
中文名称 |
(3S,5S,8R,9S,10S,13R,14S,17R)-5,14-二羟基-13-甲基-17-(5-氧代-2,5-二氢呋喃-3-基)-3-(((2R,3R,4R,5R,6S)-3,4,5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)六十氢-10H-环戊二烯并[a]菲-10-甲醛 |
英文名称 |
(3S,5S,8R,9S,10S,13R,14S,17R)-5,14-dihydroxy-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)-3-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-10H-cyclopenta[a]phenanthrene-10-carbaldehyde |
别名 |
5beta,14beta-Dihydroxy-19-oxo-3beta[(alpha-L-rhamnopyranosyl)oxy]card-20,22-enolide | HY-N1312 | HY-N2453 | Q 5 | Q2996215 | Convallatoxoside | MS-30077 | NSC 407808 | 3beta-(6-deoxy-alpha-L-mannopyranosyloxy)-5,14-dihydroxy-19-oxo-5beta-card-20(22)-enoli |
标准英文名 |
(3S,5S,8R,9S,10S,13R,14S,17R)-5,14-dihydroxy-13-methyl-17-(5-oxo-2,5-dihydrofuran-3-yl)-3-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-10H-cyclopenta[a]phenanthrene-10-carbaldehyde |
分子式 |
C29H42O10 |
分子量 |
550.65
|
精确分子量 |
550.28
|
SMILES |
[H][C@@]12CC[C@@]3(C[C@@H](O[C@@H]4O[C@H]([C@@H]([C@H]([C@H]4O)O)O)C)CC[C@@]3([C@]1(CC[C@@]5([C@@H](C6=CC(OC6)=O)CC[C@]25O)C)[H])C=O)O |
标准SMILES |
C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@H](CC[C@@]43C=O)O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@]1(O)CC[C@@H]2C1COC(=O)C=1 |
用途 |
Convallatoxin is used as a cardiotonic agent, similar to digitalis preparations, primarily for the treatment of acute and chronic heart failure; it also exhibits anti-inflammatory and antiproliferative properties, enhances ligand-induced MOR endocytosis with high potency and efficacy, activates PPARγ and inhibits NF-κB to ameliorate colitis, induces necroptosis in HaCaT cells in vitro, and demonstrates antipsoriatic activities in two mouse models of psoriasis. |
InChIKey |
HULMNSIAKWANQO-JQKSAQOKSA-N |